Dr. Lund also calls attention to our sensitivity analysis of all-cause mortality, which excluded one trial, the UK Prospective Diabetes Study (UKPDS) trial of metformin in patients with sulfonylurea failure (UKPDS-S) [4] , from the group of trials in which the comparator was placebo or usual care. This acknowledged post hoc sensitivity analysis was carried out because of the high heterogeneity in this group of studies (I 2 =50.8%), but Dr Lund correctly observes that we could equally conduct a sensitivity analysis to exclude the other large trial in this group of studies, the UKPDS trial of metformin in overweight patients (UKPDS-O). For completeness, we include here a table of relative risks for all-cause mortality, and corresponding confidence intervals and heterogeneity statistics, for all placebo-or usual-carecontrolled trials, and excluding each trial in turn (Table 1) . Exclusion of either UKPDS trial, but not any other trial in this group, reduces the I 2 statistic for heterogeneity to 0.0%.
We believe that the remarks in our paper that the summary estimates 'are dominated by the two large trials from the UKPDS group, which appear to show for metformin effects in opposite directions' and that our analyses have limitations to be overcome by future randomised trials, remain justified. We re-emphasise our observation that the average follow-up for mortality in our analysis is just 2.8 years, and that our results for all-cause mortality in particular are unlikely to fully reflect the long-term effects of metformin. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metabol 13:567-576 
